Meet with us at Clinical Trials on Alzheimer’s Disease Conference (CTAD)!
The Alzheimer’s disease research landscape is evolving rapidly as disease-modifying therapies, biomarker-driven diagnostics, and earlier intervention reshape clinical development. These advances create new opportunities—and new considerations around patient identification, endpoint selection, site readiness, safety oversight, and the operational impact of an evolving standard of care.
At CTAD 2026, connect with Premier Research’s neuroscience and Medical Affairs experts to discuss practical strategies for moving Alzheimer’s programs forward. Our team brings scientific, medical, and operational insight to support development from early planning through trial execution.
Connect with our team to discuss:
- Clinical development strategy and study design for symptomatic, early-stage, and preclinical populations
- Biomarker integration, endpoint selection, and rater and scale management
- Patient recruitment and retention strategies that account for patients, caregivers, and study sites
- Medical monitoring, safety oversight, and cross-functional risk management
On-Site
- Andreas Schreiner, Senior Vice President, Medical Affairs
- Melissa Snyder, Executive Director, Program Strategy
- Chris Foster, Senior Project Manager
Fill out the form above to schedule a meeting with our on-site team.
Meet with us in Boston to explore a patient-centered approach to navigating the next phase of Alzheimer’s clinical research.
